WO2006007429A1 - Multichemistry fractionation - Google Patents
Multichemistry fractionation Download PDFInfo
- Publication number
- WO2006007429A1 WO2006007429A1 PCT/US2005/021489 US2005021489W WO2006007429A1 WO 2006007429 A1 WO2006007429 A1 WO 2006007429A1 US 2005021489 W US2005021489 W US 2005021489W WO 2006007429 A1 WO2006007429 A1 WO 2006007429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sorbents
- biomolecular
- sorbent
- specificity
- component
- Prior art date
Links
- 238000005194 fractionation Methods 0.000 title description 29
- 239000002594 sorbent Substances 0.000 claims abstract description 284
- 238000000034 method Methods 0.000 claims abstract description 110
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 239000000463 material Substances 0.000 claims description 106
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- 230000002209 hydrophobic effect Effects 0.000 claims description 56
- 239000000523 sample Substances 0.000 claims description 52
- 239000000872 buffer Substances 0.000 claims description 43
- 239000003446 ligand Substances 0.000 claims description 27
- 238000001179 sorption measurement Methods 0.000 claims description 27
- 239000003463 adsorbent Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 238000004949 mass spectrometry Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000000926 separation method Methods 0.000 claims description 14
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims description 11
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 10
- -1 Green 5 Chemical compound 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- 238000005342 ion exchange Methods 0.000 claims description 8
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 claims description 7
- 229960002897 heparin Drugs 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- 230000002535 lyotropic effect Effects 0.000 claims description 7
- 239000008366 buffered solution Substances 0.000 claims description 6
- 238000001502 gel electrophoresis Methods 0.000 claims description 6
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000003196 chaotropic effect Effects 0.000 claims description 4
- 238000001698 laser desorption ionisation Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000010924 continuous production Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 2
- 239000012149 elution buffer Substances 0.000 claims 4
- 238000005516 engineering process Methods 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 210000002966 serum Anatomy 0.000 description 28
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 241000894007 species Species 0.000 description 22
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 19
- 230000003993 interaction Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 238000001742 protein purification Methods 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 239000004202 carbamide Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 11
- 102000009027 Albumins Human genes 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000001920 surface-enhanced laser desorption--ionisation mass spectrometry Methods 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 101001011741 Bos taurus Insulin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 3
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000012541 Fractogel® Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 101150026046 iga gene Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- QLAJPGCDKRPRKU-UYTYNIKBSA-N (2r,3r,4s,5s,6r)-3-[2-(diethylamino)ethoxy]-6-[2-(diethylamino)ethoxymethyl]oxane-2,4,5-triol Chemical compound CCN(CC)CCOC[C@H]1O[C@@H](O)[C@H](OCCN(CC)CC)[C@@H](O)[C@@H]1O QLAJPGCDKRPRKU-UYTYNIKBSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000012617 Butyl Sepharose™ 4 Fast Flow Substances 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010089814 Plant Lectins Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical class [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- TWYVVGMYFLAQMU-UHFFFAOYSA-N gelgreen Chemical compound [I-].[I-].C1=C(N(C)C)C=C2[N+](CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]3=C4C=C(C=CC4=CC4=CC=C(C=C43)N(C)C)N(C)C)=C(C=C(C=C3)N(C)C)C3=CC2=C1 TWYVVGMYFLAQMU-UHFFFAOYSA-N 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000148 multi-dimensional chromatography Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
- 239000012608 weak cation exchange resin Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
- B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28052—Several layers of identical or different sorbents stacked in a housing, e.g. in a column
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/54—Sorbents specially adapted for analytical or investigative chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/60—Use in several different columns
- B01J2220/603—Use in several different columns serially disposed columns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44773—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis
Definitions
- the present invention relates generally to the fields of protein chemistry and analytical chemistry, and, more particularly, to the purification of proteins and other chemicals of biological origin from complex mixtures of such chemicals.
- the invention has applications in the areas of protein chemistry, analytical chemistry, clinical chemistry, drug discovery, and diagnostics.
- ICAT methodology involves an avidin-affinity separation of biotinylated tagged trypsic peptides (Issaq, J.H., et al 2002,Hochstrasser, et al. 2000; Moseley, A.M., Trends in Biotechnology, 2001, 19:S10).
- fractionation methods use ion exchange (Lopez, M.F., 2000,17), IMAC for calcium binding protein (Lopez, M.F., et al, Electrophoresis, 2000, 21:3427-3440) or phospho-proteins (Hunt, D.F., et al, Nat. Biotechnol, 2002, 20:301-305), hydrophobic (Lopez, 2000), heparine (Hochstrasser, et al. 2000) or lectin (Hochstrasser, et al. 2000; Lopez, 2000; Regnier, F., et al, J. Chromatography
- Two- dimensional liquid chromatography used for intact protein fractionation or their trypsic digests generally uses RP for the second dimension, combined with ion exchange (Yates, IR., Nature Biotech, 1999, 17:676-682, Unger, K.K., et al, Anal. Chem., 2002, 74:809- 820), chromato-focusing (Wall, D., et al, Anal. Chem., 2000, 72:1099-1111), size exclusion (Opiteck, G., Anal.
- Multidimensional chromatography in proteomic fractionation generally never exceed two dimensions due to high number of fractions to manage (pH-adjustment, desalting, re-injection in second dimension) and analyze, especially when a tedious analytical methods as 2DE makes the final bottleneck.
- the present invention addresses these and other needs by providing methods, apparatuses, and kits that allow more efficient and reliable purification of complex mixtures of biological substance, especially proteins.
- the methods, apparatuses, and kits provided by the invention can be used in conjunction with additional purification and analytical techniques to identify and quantify the biological substances present in a given sample, especially proteins.
- the methods, apparatuses, and kits of the invention have important applications to proteomics, diagnostics, and drug discovery among other fields.
- the invention relates to methods for prefractionating a complex mixture including a plurality of different biomolecular components.
- One particular embodiment of the methods provided by the invention include providing a series of different sorbents, introducing the complex mixture to the series of sorbents, contacting serially the complex mixture with each of the sorbents, and capturing biomolecular components from the complex mixture on the sorbents so that each of the sorbents captures a substantially unique subset of said plurality of biomolecular components.
- the method includes contacting the complex mixture with at least two different
- nr ⁇ -U-ISRQI 1 sorbents having different specificities including sorbents having high specificity, moderate specificity, and low specificity.
- a still more specific embodiment of the method includes selecting the sorbents to effect substantially complete capture of all biomolecular components from the complex mixture.
- a method comprising providing a series of at least three different sorbents arranged in a progression of decreasing specificity; introducing a complex mixture to said series of sorbents; contacting serially said complex mixture with each of said sorbents; and capturing biomolecular components from said complex mixture on said sorbents, wherein each of said sorbents captures a substantially unique subset of said plurality of biomolecular components.
- the invention provides an apparatus for prefractionating a complex mixture including a plurality of biomolecular components.
- the apparatus of the invention includes a plurality of sorbents characterized by different adsorption specificities for different biomolecular component types coupled in a series arrangement.
- the sorbents are arranged such that introduction and passage of a buffered solution including (i) the complex mixture and (ii) a buffer that is compatible with the sorbents serially through the series arrangement of sorbents is effective to remove at least a portion of the mixture components from the mixture components from.
- the sorbents are arranged to define a progression in affinities for at least one biomolecular component type.
- the apparatus defines a substantially contiguous component-sequestering body.
- the apparatus defines a substantially linear progression of adsorption specificities for at least one of the biomolecular component types.
- an apparatus comprising at least three sorbents characterized by different adsorption specificities for different biomolecular component types coupled in a serial arrangement of decreasing specificity.
- an apparatus can comprise in sequence: (a) a high specificity sorbent, (b) a moderate specificity sorbent, and (c) a low specificity sorbent, and said sorbents being coupled in a serial arrangement whereupon introduction and passage of a buffered solution including (i) a complex mixture and (ii) a buffer that is compatible with said materials serially through said serial arrangement
- the invention provides a kit for preparing an apparatus for prefractionating a complex mixture including a plurality of biomolecular components.
- the kit provided by the invention includes a plurality of sorbents characterized by different adsorption specificities for different biomolecular component types and a compatible buffer chosen such that when the materials are coupled in a series arrangement, introduction and serial passage of a buffered solution including (i) the complex mixture and (ii) the buffer through the series arrangement of materials is effective to capture substantially all of the plurality of biomolecular components from the complex mixture.
- the biomolecular components isolated using the methods, apparatuses, and kits of the invention are eluted from the sorbents, for example, by at least one sorbent to water, a chaotropic agent, a lyotropic agent, an organic solvent, a change in ionic strength, a change in pH, a change temperature, a change pressure, or a combination of thereof.
- the isolated components can then be detected and identified using methods such as mass spectrometry, mono- and multi-dimensional gel electrophoresis, fluorimetric methods, high-pressure liquid chromatography, medium-pressure liquid chromatography.
- Figure 1 illustrates an embodiment of the method of the invention.
- Figure 2 illustrates the reduction in dynamic range of a sample, and the capture of the biomolecular components in the sample, by serial passage of the sample over successive sorbents ranging from sorbents having high specificity for abundant biomolecular species though sorbents having low specificity for any particular biomolecular species, according to one embodiment of the invention.
- Figure 3 is a graph comparing the fractionation method of the invention with other fractionation methods.
- Figure 4 is a graph of the results of the experiment described in Example 2 showing the superior resolving capabilities of the invention.
- a sample spiked with insulin was detected on a specific sorbent chemistry (MEP -HYPERCEL, column A).
- MEP -HYPERCEL specific sorbent chemistry
- Figure 5 is a graph of the results of the experiment described in Example 2 showing the superior resolving capabilities of the invention.
- the ability of the method of the invention to capture insulin on a specific sorbent chemistry provides detection at concentrations as low as 1 fMol/ ⁇ L in human serum (column A).
- Q-HyperD single-chemistry, fractionation methods
- a 2-log reduction in sensitivity was observed (100 fMol/ ⁇ L, column B).
- Figure 6 is a mass spectrograph providing SELDI MS data obtained using a ProteinChip ® Array CMlO.
- "a” initial serum proteins
- "b” C2 column
- "c” C4 column
- “d” C8 column.
- Molecular weight range explored is 2000 - 10000 Da.
- Figure 7 is a mass spectrograph providing SELDI MS data obtained using a ProteinChip ® Array QlO.
- "a” initial serum proteins
- "b” C2 column
- "c” C4 column
- “d” C8 column.
- Molecular weight range explored is 1000 - 6000 Da.
- Figure 8 provides SDS PAGE analysis of protein fractions under reduced conditions, "a” represents proteins stained after migration with Coomassie blue; “b” represents fraction eluted from C3, C4, C6 and FT (flowthrough), using a silver staining.
- Figure 9 is a mass spectrograph providing SELDI MS analysis of protein fractions eluted from Cl, C2, C3, C4, C6 and FT (flowthrough), using a QlO ProteinChip Array using a physiological buffer containing 2M urea.
- Figure 10 is a mass spectrograph providing SELDI MS analysis of protein fractions eluted from Cl, C2, C3, C4, C6 and FT (flowthrough), using a CMlO ProteinChip Array using a physiological buffer containing 2M urea.
- the present invention provides methods and systems for reducing the complexity of complex mixtures containing biomolecular components, i.e., chemical species generated by biological processes such as, but strictly limited to: proteins, nucleic acids, lipids, and metabolites.
- biomolecular components i.e., chemical species generated by biological processes such as, but strictly limited to: proteins, nucleic acids, lipids, and metabolites.
- the methods and systems provided by the present invention allow isolation and detection of biomolecular components with greater sensitivity and efficiency that heretofore possible.
- FIG. 1 provides an illustration of one embodiment of invention at 100.
- a sample solution containing a complex mixture including a plurality of different biomolecular components 101 is introduced to a sample fractionation column 102 for at least partial resolution as described hereinbelow.
- Column 102 includes a plurality of sorbent materials 104, 106, 108, and 110 arranged serially and through which solution 101 is passed to contact serially thereby each of the sorbent materials after which any remaining solution is eluted to a receptacle 112.
- the sorbent materials are chosen such that substantially all of the biomolecular components are captured by sorbents 104-110.
- each of the sorbents 104—110 captures a substantially unique subset of the plurality of biomolecular components.
- sorbent 104 is effective to capture subset 114
- sorbent 106 is effective to capture subset 116
- sorbent 108 is effective to capture subset 118
- sorbent 110 is effective to capture subset 120.
- the sorbents including the captured biomolecular components, are isolated (i.e., removed from the column); and the subset components are eluted or otherwise removed from the sorbents for further processing as discussed in greater detail below.
- capture refers to the ability of a sorbent to attract and reversibly retain one or more biomolecular components in solution 101 such that certain subsets of the
- nrv3 -1/H -3RQ-1 -i biomolecular components are substantially completely removed from solution 101 during passage through column 102.
- a sorbent's ability to retain a biomolecular component inherently includes a specificity of the sorbent for certain biomolecular components that is defined by the interaction between the sorbent and a biomolecular component under the ambient conditions in which the sorbent and the solution are in contact (e.g., the temperature and ionic strength or pH of the solution being passed through the column).
- the interaction can be any physicochemical interaction known or believed to be sufficient to cause sorption of a biomolecular component (or subset of biomolecular components) by the sorbent to substantially completely deplete the solution of the biomolecular component (or subset), but still allow subsequent elution of the captured biomolecular component(s).
- Typical sorbent-biomolecular component interactions include without limitation: ion exchange (cation or anion); hydrophobic interactions; biological affinity (including interactions between dyes and ligands with proteins, or lectins with glycoconjugates, glycans, glycopeptides, polysaccharides, and other cell components); immunoaffinity (i.e., antigen- antibody interactions or interactions between fragments thereof); metal-chelate or metal-ion interactions, interactions between proteins and thiophilic materials, interactions between proteins and hydroxyapatite, and size exclusion.
- Many such materials are known to those having skill in the art of protein or nucleic acid purification. These materials can be made using known techniques and materials or purchased commercially. Descriptions of these materials and examples of methods for making them are described in Protein Purification Protocols 2 nd Edition, Cutler, Ed. Humana Press 2004, which is incorporated herein by reference in its entirety for all purposes.
- Ion exchanging materials include strong and weak cation- and anion exchange resins.
- Strong cation exchanging ligands include sulfopropyl (SP) and methyl sulfonate (S).
- Weak cation exchange ligands include carboxymethyl (CM).
- Strong anion exchange ligands include quaternary ammonium and quaternary aminoethyl (QAE).
- Weak anion exchange ligands include diethylaminoethyl (DEAE).
- ion-exchange materials include without limitation, the materials sold commercially under the trade names: Q-, S-, DEAE- and CM CERAMIC HYPERD®; DEAE-, CM-, and SP TRISACRYL®; M-, LS-;
- ion exchange materials are sold under the trade names: DE AE-TRIS ACRYL®, DEAE SEPHAROSE®, DE AE-CELLULO SE, DIETHYLAMINOETHYL SEPHACEL®, DEAE SEPHADEX®, QAE SEPHADEX®, AMBERJET®, AMBERLITE®, CHOLESTYRAMINE RESIN 5 CM SEPHAROSE®, SP SEPHAROSE®, SP- TRISACRYL®, CELLULOSE PHOSPHATE 5 CM-CELLULOSE, CM SEPHADEX®, SP SEPHADEX®, and AMBERLITE® from Sigma- Aldrich Co. of St. Louis, MO.
- Other commercial sources for ion exchange materials include Amersham Biosciences (www.amersham.com). Still other materials will be familiar to those having skill in the art of protein purification.
- HIC hydrophobic interaction chromatography
- HIC materials include the materials sold under the trade names: TOYOPEARL and TSKGEL from Tosoh Bioscience LLC of Montgomeryville, PA.
- An equivalent material is sold commercially under the trade name MEP HYPERCEL (Ciphergen Biosystems, Fremont, CA). Still other materials will be familiar to those having skill in the art of protein purification.
- Affinity materials include any materials effective to attract and sorb biomolecular components on the basis of structural interactions between a biomolecular component and a ligand such as: antibody-antigen, enzyme-ligand, nucleic acid-binding protein, and hormone- receptor.
- the interactions can be between naturally occurring or synthetic ligand and a biomolecular component.
- the ligands can be either mono-specific (e.g., a hormone or a
- group-specific e.g., enzyme cofactors, plant lectins, and Protein A
- group-specific ligands suitable for the present invention are provided in Table 1.
- affinity materials include those sold under the trade names: PROTEIN A CERAMIC HYPERD® F, BLUE TRISACRYL® M, HEPARIN HYPERD® M, and LYSINE HYPERD® from Ciphergen Biosystems (Fremont, CA). Still other commercially available materials are provided by commercial suppliers including Amersham Biosciences ( ' www.amershambioscience.com ' ) and Sigma-Aldrich (www.sigmaaldrich.com). Still other materials will be familiar to those having skill in the art of protein purification.
- the affinity materials are derived from reactive dyes are used to create sorbents.
- Dye-ligand sorbents are often useful for binding proteins and enzymes that use nucleic acid cofactors, such as kinases and dehydrogenases; but other proteins, including serum albumins, can be sorted efficiently with these sorbents as well.
- Suitable commercially available materials include those sold under the trade names REACTIVE BLUE, REACTIVE RED, REACTIVE YELLOW, REACTIVE GREEN, and REACTIVE BROWN (Sigma-Aldrich); DYEMATRIX GEL BLUE, DYEMATRIX GEL RED, DYEMATRIX GEL ORANGE, and DYEMATRIX GEL GREEN (Millipore, Billerica, MA); and the Procion dyes known as Blue H-B (Cibacron Blue), Blue MX-R, Red HE-3B, Yellow H-A, Yellow MX-3r, Green H-4G, Green H-E4BD, Brown MX-5BR. Still others will be familiar to those having skill in the art of protein purification.
- Useful sorbents can also be constructed from lectins to separate and isolate glycoconjugates, glycans, glycopeptides, polysaccharides, soluble cell components, and cells. Suitable lectins include those shown in Table 2.
- Immunoaffmity materials can be made using standard methods and materials known to those having skill in the protein purification arts ⁇ See, e.g., Protein Purification Protocols).
- Commercially available immunoaffinity material include those sold by Sigma- Aldrich (www.sigmaaldrich.com ' ) and Amersham Biosciences (www.amersham.com).
- metal-ion affinity (IMAC) materials can be prepared using know materials and methods (See, e.g., Protein Purification Protocols.), or purchased commercially (e.g., from Sigma-Aldrich (www.sigmaaldrich.com) or Amersham Biosciences (www.amersham.com)).
- Common metal include Ni(II), Zn(II), and Cu(II).
- G glycine
- H histidine
- HT/HTP hydroxyapatite
- TAC thiophilic sorbents
- Commercial sources include Bio-Rad of Hercules, CA (trade name CHT), Ciphergen Biosystems of Fremont, CA (trade name HA ULTROGEL®), and Berkeley Advanced Biomaterials of San Leandro, CA (trade name HAP).
- Thiophilic sorbents also can be made using methods and materials known in the art or protein purification or purchased commercially under the trade names: MEP HYPERCEL (Ciphergen Biosystems, Fremont, CA), THIOPHILIC UNIFLOW and THIOPHILIC SUPERFLOW (Clonetech, Palo Alto, CA), THIOSORB (Millipore, Billerica, MA), T-GEL (Affiland, Ans-Liege, Belgium), AFFI- T (Ken-en-Tec, Copenhagen, Denmark), HI-TRAP (Amersham Biosciences, Piscataway, NJ), and FRACTOGEL (Merck KgA, Poole Dorset UK).
- sorbents have specificities for different biomolecular components.
- specificity relates to the number of different biomolecular species in a given sample which a sorbent can bind.
- sorbents can be grouped by their relative degrees of specificity, for example high specificity sorbents, moderate specificity sorbents, and low specificity sorbents.
- High specificity sorbents include those materials that generally have a strong preference to sorb certain biomolecules or subsets of biomolecules. Often such materials include highly biospecific sorption interactions, such as antibody-epitope recognition, receptor-ligand, or enzyme-receptor interactions.
- sorbents include Protein A-, Protein G-, antibody-, receptor- and aptamer-bound sorbents.
- Moderate specificity sorbents include materials that also have a degree of bispecific sorption interactions but to a lesser degree than high specificity materials, and include: MEP,
- Low specificity sorbents include materials that sorb bimolecular components using bulk molecular properties (such as acid-base, dipole moment, molecular size, or surface electrostatic potential) and include: zirconia, silica, phenylpropylamine cellulose, ceramics, titania, alumina, and ion exchangers (cation or anion).
- the progression from high specificity to low specificity serves a particularly useful purpose.
- it allows fractionation of the proteins in the sample into largely exclusive groups, but of decreased complexity.
- the proteins in the various fractions are more easily resolved by the detection method chosen.
- a low- or moderate- specificity resin might have affinity for or bind to many biomolecules in a sample, including ones in very high concentration.
- a high specificity sorbent that is directed to the protein in high concentration before exposing to the moderate- specificity sorbent, one can remove most or all of the high concentration protein. In this way, the set of biomolecules captured by the moderate specificity sorbent will largely or entirely exclude the high concentration biomolecule.
- the strategy is to remove at earlier stages biomolecules, e.g., proteins, that would otherwise be captured by sorbents at later stages of the fractionation process so that at each stage, the complexity of the biomolecules passing to the next stage is decreased.
- the solution of biomolecular components is contacted with at least three different sorbents from among high-, moderate-, or low- specificity sorbents.
- the solution will be contacted with one, two, or three or more materials of the same degree of specificity (e.g., two materials of moderate specificity or three materials of low specificity).
- the solution is contacted with a plurality of sorbents that define a progression from high specificity to low specificity.
- the solution is contacted with a plurality of sorbents that define a progression from high specificity to low specificity.
- the sorbent materials are arranged to provide a substantially linear progression of specificities.
- the sorbent materials form a substantially contiguous body.
- the sorbents are mutually orthogonal, i.e., the ability of each sorbent is substantially selective for a unique biomolecular component or subset of biomolecular components.
- the sorbents are chosen such that at least one sorbent is a high specificity sorbent and at least one other sorbent is either a moderate- or low specificity sorbent.
- the sorbents are chosen such that at least one sorbent each is a high specificity sorbent, a moderate specificity sorbent, and low specificity sorbent.
- At least two sorbents are chosen from two classes of high specificity sorbents, moderate specificity sorbents, and low specificity sorbents. In another embodiment, at least two sorbents are high specificity sorbents and at least one sorbent is a low specificity sorbent.
- a series of sorbents having the same degree of specificity can be used.
- the sorbents possess the same relative degree of specificity they have different absolute specificities, i.e. each sorbent individually binds to different numbers of species of bimolecular components in a sample.
- sorbents having the same degree of specificity are utilized, they are arranged to provide a substantially linear progression of adsorption from highest specificity to lowest specificity.
- a second sorbent has decreased specificity compared with a first sorbent if, when exposed to the same sample, the second sorbent binds more species from the sample than the first sorbent.
- each of the sorbents in the series can be a hydophobic sorbent.
- each sorbent comprises a hydrocarbon chain and, optionally, an amine ligand, and the hydrocarbon chain of each sorbent in the series comprises more carbons than the previous sorbent.
- Suitable terminal binding functionalities include, but are not limited to, primary amines, tertiary amines, quaternary ammonium salts, or hydrophobic groups.
- the sorbents can comprise, for example, hydrocarbon chains selected from the group consisting of Cl, C2, C3, C4, C5, C6 and so on.
- proteins are characterized by their hydrophobic degree (called also hydrophobic index) which is the result of the content and the sequence of lipophilic amino acids such as leucine, isoleucine, valine and phenylalanine.
- hydrophobic degree proteins associate with hydrophobic interaction adsorbents in the presence of lyotropic salts. The strength of adsorption depends on both the hydrophobic
- nn? 14-1-5 ⁇ Q1 -i character of the sorbent and the concentration of lyotropic salts When sorbents are designed in such a way so that they are capable to associate proteins in physiological conditions, the only variable will be the structure of the sorbent itself.
- the hydrophobicity degree of a sorbent depends on the length of the hydrocarbon chain of the ligand used and its density. However, if the ligand density is fixed only the length of the hydrocarbon chain would play the role of adsorbent moiety. In practice it is possible to synthesize sorbents with ligands of different chain length and the same ligand density. If the ligand is selected among those that produce adsorption in physiological conditions, it is possible to put in place a system where the discrimination will be dependent only on the solid phase.
- the sequence of superimposed sorbent should be composed of the mildest hydrophobic sorbents first, followed by a sequence of sorbents of growing hydrophobicity degree. To have the system work as expected, it is necessary to work in under-loading conditions so that the first layer of the column will deplete for the most hydrophobic species, the second layer will then remove a group of less hydrophobic species and so on. The last section of sorbent (the most hydrophobic) will finally remove the least hydrophobic proteins.
- Adsorption is operated using the same buffer for all column sections; the preferred buffer is a physiological phosphate buffer containing 0.15 M sodium chloride. To this buffer modifiers could be added to modulate the conditions for protein adsorption (see variations to the general method).
- the sorbent is made using hydrocarbon chains of different length so that to drive the degree of hydrophobicity of the columns sections. More particularly the hydrophobic ligands
- 002.1413891.1 are primary amines on one extreme and a hydrophobic moiety at the other extremity.
- the first ligand of the series is methylamine, followed by ethylamine, propylamine, butylamine, pentylamine, hyxylamine and so on.
- the longest hydrophobic amine of practical interest in the present application is octadecylamine.
- Preferred matrix material for the preparation of the solid sorbents is cellulose and other polysaccharides.
- the preferred activation method for the introduction of the hydrophobic ligand is allyl bromide.
- a typical example of separation of proteins by their hydrophobicity degree is as follows:
- Pack each sorbent is three superimppsed Promega columns each filled with 125 ⁇ L of sorbent.
- the columns are then equilibrated with a physiological phosphate buffered saline followed by the injection of 200 ⁇ liters of albumin-depleted serum (protein concentration: 5 mg/mL).
- the sample is then pushed through the sectional columns using PBS. Once the adsorption phase is over, sectional columns are disconnected and proteins adsorbed on each of them are eluted using a mixture of TFA/ ACN/ Water
- Types of hydrophobic ligands useful in this method include aliphatic linear chains such as methyl through octadecyl; they can be branched aliphatic hydrocarbon chains; they can be cyclic structures or aromatic hydrophobic structures. They can also be combinations of aliphatic and aromatic structures.
- R 1 , R 2 , R 4 , and R 5 are independently selected from H, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -alkyl-C 1-6 -alkoxy, aryl, C 1-6 -alkaryl, -NR 5 C(O)R", - C(O)NR 5 R", and hydroxy.
- R 1 , R 2 , R 4 , and R 5 are independently selected from H and C 1-6 -alkyl. The most preferred embodiments are those in which R 1 and R 2 are H, while R 4 and R 5 are C 1-6 -alkyl.
- R 6 is selected from the group consisting of H, C ⁇ -alkyl, aryl, C 1-6 -alkaryl, -C(O)OH, -S(O) 2 OH, and -P(O)(OH) 2 .
- the terminal binding functionality as a whole is thus represented generally by -(NR 5 )(R 3 -) Y- R 6 in formula (I).
- d 5 is 1, thus giving the terminal binding functionality as an amine (when (R 3 O Y is absent) or a quaternary ammonium salt (when (R 3' )Y is present).
- R 6 is preferably C 1-6 -alkyl.
- d 5 is 0, thus providing for a terminal binding functionality that is represented predominantly by R 6 .
- R 6 is preferably chosen from H, C 1-6 - alkyl, aryl, and C ⁇ -alkaryl groups when a hydrophobic terminal binding functionality is desired.
- the terminal binding functionality is a cation exchange group
- R 6 is accordingly chosen from -C(O)OH, -S(O) 2 OH, and -P(O)(OH) 2 .
- X and Y represent anions. No particular requirements restrict the identity of these anions, so long as they are compatible with the prescribed use of the chromatographic material.
- Exemplary anions in this regard include fluoride, chloride, bromide, iodide, acetate, nitrate, hydroxide, sulfate, carbonate, borate, and formate.
- a, a', a", and a' are 2 or 3, more preferably at least two of a, a', a", and a'" are 2 or 3, and most preferably a is 3 while a' is 2, 3, 4, 5, or 6.
- the linker is thiophilic in addition to being hydrophobic. Accordingly, one or both of het and het' in formula (I) are chosen from increasingly thiophilic groups -S-, -S(O)-, and -S(O) 2 -, S being most preferred. In the most preferred chromatographic material, het is S while het' is absent.
- chromatographic materials are particularly efficacious. This is so because the materials present significant patches or regions of hydrophobicity in the hydrophobic linker, which property is generally achieved by coupling alkylene fragments together.
- the hydrophobic linker can comprise at least two unsubstituted propylene groups.
- the hydrophobic linker can comprise at least one unsubstituted ethylene group and at least one mono-substituted propylene group.
- at least one Of (CR 1 R 2 V (CRiRaV, (CR 1 R 2 V and (CR 1 R 2 V- is -CH 2 -CH 2 - and at least one is -C 3 H 5 (OH)-.
- the hydrophobic linker can comprise at least two mono-substituted propylene groups.
- At least two of (CR 1 R 2 V (CRiR 2 V, (CR 1 R 2 V and (CR 1 R 2 V- are -C 3 H 5 (OH).
- the alkylene groups can be separated by a heteroatom or a group comprising a heteroatom, such as -O-, -S- , -NH- or -C(O)N(H)-. All combinations of these are contemplated.
- one embodiment incorporates an unsubstituted propylene group and an unsubstituted ethylene group that are separated by het or het' in general formula (I), in which, for example, a (or a") is 3, a' (or a"' is T), and b (or b') is 1.
- a (or a") is 3
- a' (or a"' is T
- b (or b') is 1.
- the hydrophobic linker comprises two unsubstituted propylene groups that are separated by het or het'.
- a and a' are both 3 while b is 1, or a" and a"' are both 3 while b' is 1.
- the hydrophobic linker comprises an unsubstituted propylene group and at least an unsubstituted pentylene group that are separated by het, thus corresponding to a being 3, a' being 5, and b being 1 in general formula (I).
- the propylene group can be substituted once with a hydroxyl group.
- the hydrophobic linker comprises two unsubstituted propylene groups that are separated by one amino moiety. Referring therefore to general formula (I), a or a' is 3, the other being 0; a" or a'" is 3; het and het' are absent; and c is 0 while d is 1.
- general formula (I) the wavy line represents the solid support to which the hydrophobic linker is attached. It is understood for the purpose of clarity, however, that general formula (I) depicts only one (1) linker-terminal binding functionality as being tethered to the solid support.
- the inventive chromatographic materials actually exhibit linker-terminal binding functionality densities of about 50 to about 150 ⁇ mol/mL chromatographic material, preferably about 80 to about 150 ⁇ mol/mL, and more preferably 100 to about 150 ⁇ mol/mL.
- linker that attaches the ligand to the matrix, which makes it possible to function at physiological ionic strength include a nitrogen, a sulfur group or an oxygen atom.
- the activation of the solid matrix can be accomplished using the well known chemical approaches used in affinity chromatography.
- the preferred one involves the use of allyl groups. This is obtained by reacting the solid phase matrix with allyl-bromide or allyl- glycydyl-ether.
- Buffers for protein loading is most generally a physiological buffer such as PBS.
- PBS physiological buffer
- a large number of variations are possible in terms of pH, ionic strength and nature of components. Modifiers to the adsorption buffer is also a possibility especially when the
- Desorbing solutions are composed of any possible chemical component capable to elute proteins from the sorbent. Most generally this is composed of a hydro organic mixture of acidic pH such as trifluoroacetic acid, acetonitrile and water. Desorption solutions may however be of alkaline pH and containing alcohols or detergents or chaotropic agents.
- Superimposed layers can go from two layers up to ten or even 20 layers of different hydrophobic sorbents of growing hydrophobic degree.
- Devices used to apply the described principle can be superimposed columns where the outlet of the upper column is directly linked to the inlet of the following column. It can be a set of superimposed 96-well filtration plate or any possible device that allows injecting sequentially a protein solution throughout a series of solid phase sorbents in packed and slurry mode.
- Proteins to separate by using the described method are from biological fluids such as serum, urine, CSF; it can be a tissue soluble extract.
- biological fluids such as serum, urine, CSF
- a specific aspect contemplated by this principle is the separation of components from membrane extracts. They can be done in the presence or urea and then loaded on the sequence of the columns.
- the above-described materials are used in any manner and with any apparatus known to those of skill in the art to separate biomolecular materials from complex mixtures of such.
- Commonly known formats for using these materials include: column chromatography, medium-pressure liquid chromatography, high-pressure liquid chromatography, flat surfaces or other two-dimensional arrays (such as PROTEINCHIP® arrays from Ciphergen Biosystems of Fremont, CA), or 96-well filtration plates. The latter are useful for parallel fractionations.
- the apparatus used for separation may further include the addition of an electric potential to allow isoelectric focusing. Still more formats will be know to those of skill in the protein purification arts.
- the sorbents are chosen such that the biomolecular materials of the greatest concentrations are removed first.
- the protein composition of human serum includes upwards of 90% of the following: albumin, IgG 3 transferrins, ⁇ -1 anti-trypsin, IgA, IgM, fibrinogen, ⁇ -2-macroglobulin, and complement C3.
- About 99% of human serum further includes: apolipoproteins Al and B; lipoprotein A; AGP, factor H; ceruloplasm; pre ⁇ albumin; complement factor B; complement factors C4, C8, C9, and C19; and ⁇ - glycoprotein).
- the reaming 1% comprise the so-called deep proteome.
- Arranging the sorbents such that a Protein A sorbent and a Cibacron Blue sorbent are the first two sorbents can reduce the dynamic range of human serum from approximately 10 8 to about 10 5 , thereby allowing capture of lower abundance biomolecular components for identification and quantitation.
- placing a sorbent such as phenylpropylamine cellulose at the end of the column is useful to catch any remaining biomolecular components in the sample.
- the initial sorbent(s) are too general (i.e., have low specificity), then too much material can be sequestered with the first two sorbents, which degrades the usefulness of the remaining sorbents.
- the sorbents are chosen such that the first sorbent, or first and second sorbents combined, provide a reduction in the dynamic range of the sample by a factor of at least 10, more specifically a factor of at least 100, and, still more specifically a factor of at least 1,000.
- the invention provides a method for depleting highly abundant biomolecular components from a complex mixture that includes a plurality of such biomolecular components of different concentrations, comprising: contacting said complex mixture with a biospecific adsorbent material to provide thereby a low-abundance complex mixture; and contacting said low-abundance complex mixture with, in sequence, a mixed-mode adsorbent material and a non-specific adsorbent material to provide thereby a depleted complex mixture that comprises those biomolecular components having concentrations of less than about 5% of the concentrations of said highly abundant biomolecular components.
- the method of the invention provides a complex mixture that comprises those biomolecular components having concentrations of less than about 1% of the concentrations of said highly abundant biomolecular components.
- the method of the invention provides a complex mixture that comprises those biomolecular components having concentrations of less than about 1% of the concentrations of said highly abundant biomolecular components.
- the method of the invention provides a depleted complex mixture that comprises those biomolecular components having concentrations of less than about 0.1% of the concentrations of said highly abundant biomolecular components.
- the method of the invention provides a depleted complex mixture that comprises those biomolecular components having concentrations of less than about 0.01% of the concentrations of said highly abundant biomolecular components.
- the method of the invention provides a depleted complex mixture that comprises those biomolecular components having concentrations of less than about 0.001% of the concentrations of said highly abundant biomolecular components.
- the invention provides a complex mixture as described herein, in which the depleted mixture is enriched for species which, in the original mixture, comprised less than 5% of the total protein mass; more specifically, less than about 1% of the total protein mass; still more specifically less than about 0.1% of the total protein mass; yet more specifically less than about 0.01% of the total protein mass; and still yet more specifically less than about 0.001% of the total protein mass.
- FIG. 2 This aspect of the invention is illustrated in Figure 2 at 200, in which a complex sample, e.g., human serum, having at least one biomolecular component of large concentration, such as immunoglobulins (IgG, transferrin, ⁇ -1 anti-trypsin, IgA, IgM, and haptoglobin) and albumin, is sorbed by a first sorbent 202 which reduces the dynamic range of component concentrations.
- sorbent 202 can be Protein A, which has a high specificity for immunoglobulins. Exposure of this material to a second sorbent 204 provides further reduction of dynamic range.
- Such a sorbent can be another having a large ability to sorb additional immunoglobulins, albumin, and clotting factors, or other species of predominance.
- a sorbent is Cibachron Blue or heparin.
- Such sorbents can reduce dynamic range by factors of 10, or 100, or 1,000 as discussed above. Further exposure to sorbent 206 allows capture of the lesser abundant components.
- Such sorbents can include mixed-mode materials, such as dyes, chelators, or antibodies directed to specific components.
- the remaining components in the sample are exposed to a low specificity material 208, such as phenylpropylamine, silica, or zirconia. Finally, the remaining eluent is collected at 210.
- serum is a complex biological fluid having a large dynamic range of protein concentrations (-10 ). Proteins at the highest concentrations include albumins and immunoglobulins. Accordingly, as illustrated in the Examples, a useful sequence of sorbents places those sorbents having a large ability to remove the dominating proteins in the early stages of the fractionation (e.g., at the top of the column) to remove those proteins from the sample first. Following the first sorbent(s) are moderate- and low specificity sorbents that are effective to remove the lower abundance proteins. However, high specificity sorbents, such as resin-mounted antibodies can be used to trap specific lower abundance biomolecules as well.
- Protein A -HyperD (captures immunoglobulins)- Blue Trisacryl M (captures albumin)- Heparin-HyperD - MEP-HyperCel — Green 5-agarose — Zirconia oxide - Phenylpropylamine-Cel. Protein A removes immunoglobulins. Blue Tris Acryl M removes albumin. Heparin-HyperD removes various clotting factors (from plasma). MEP-HyperCel removes proteases. Green 5 (a mixed-mode sorbent) removes proteins having net positive surface charges. Of course, other complex biological fluids also can be prefractionated using the disclosed methods.
- the buffer can be any buffer solution that is compatible with the various sorbent materials used in the fractionation, i.e., such that the buffer does not substantially degrade the ability or performance of the sorbent. Such considerations will be familiar to those of skill in the protein purification arts.
- the buffer has neutral pH or a pH value within physiological limits. The latter is useful for samples derived from bodily fluids, such as blood.
- the buffer is determined by first estimating a buffer formulation using the technical characteristics of the sorbents, and then iteratively adjusting the buffer to optimize the fractionation of a sample run on the column. Such optimization includes determining the number of spots produced on a subsequent 2D-gel or the number of peaks identified by a mass spectrographic analysis such as Surface Enhanced Laser Desorption Ionization (SELDI).
- the test material or sample may also be spiked with a known material to determine if that material is substantially sorbed by a particular sorbent material.
- the buffer can be
- 002.1413891.1 adjusted to a final formulation using such isolation as a formulation criterion.
- Other criteria can be used, as will be apparent to those of skill in the protein purification arts.
- one criterion may be the efficiency of albumin or immunoglobulin removal from the sample by the first sorbent material.
- the sample solution is prepared and the column loaded with the solution.
- the determination of the sample concentration and amount of solution loaded on the column will be determined using techniques known to those of skill in the protein purification arts.
- the operator will prepare one, two, or more test columns to determine an optimal concentration and loading.
- the sample is diluted about five-fold to provide about a total volume of 100 ⁇ L and loaded onto prepared 96-well plates.
- about 20 ⁇ L of a sample is diluted to about 200 ⁇ L and pumped onto a prepared column using a syringe pump.
- the solution is allowed to traverse the sorbents in the column or stacked plates (or other appropriate apparatus) such that biomolecular components in the sample contact and either captured or sequestered by a sorbent or pass to the next sorbent.
- each subset of biomolecular materials is isolated with substantially a single sorbent such that no substantial quantity of biomolecular components elutes from the apparatus.
- the sorbents form a contiguous biomolecular-sequestering body.
- the contacting of a complex mixture to a series of sorbents occurs as a continuous process, without interruption or additional processing between the different sorbents in the series.
- each sorbent material can be excised from the body (e.g., by cutting) for subsequent processing of the biomolecular components sorbed thereby.
- a segmented column such as that sold under the trade name WIZARD, individual elements holding the sorbent and sorbed materials can be removed for later processing.
- WIZARD a segmented column
- an apparatus comprising at least three detachable segments wherein each segment comprises a sorbent having a different adsorption
- each segment ideally comprises attachment means for in ⁇ flow and out-flow tubes and means for retaining the sorbent in the segment.
- a multi-well filtration plate can be used in this manner.
- the fluidics device disclosed in U.S. Provisional Application No. 60/684,177, filed on May 25, 2005, which is hereby incorporated by reference provides a multi-well plate with detachable segments and would be useful as a platform in the present invention.
- the sequestered biomolecular material can be eluted using known materials and techniques that are appropriate for the sorbent and biomolecular material.
- suitable elution methods include, but are not limited to: exposure to water, a chaotropic agent, a lyotropic agent, an organic solvent, change in ionic strength, change in pH, change in temperature, change in pressure, or a combination of any two or more of the foregoing.
- the isolated biomolecular materials can be subjected to further operations.
- the eluted biomolecular components are subjected to a second separation procedure.
- the second separation procedure can be another fractionation as provided by the present invention, a conventional fractionation procedure, one-, two-, or multi-dimensional gel electrophoresis, mass spectrometry, and medium- or high-pressure liquid chromatography.
- the chemical identity of a biomolecular component is determined.
- Such determination can be done by fluorometry, mass spectrometry (including deposition of the component material on a SELDI probe followed by laser desorption-ionization mass spectrometry), one-, two-, or multi-dimensional gel electrophoresis, and medium- or high-pressure liquid chromatography.
- Other suitable methods include amino- or nucleic acid sequence analysis, nuclear magnetic resonance, and X-ray crystallography individually or in combination. Still more will be apparent to those of skill in the protein chemistry arts.
- Example 1 75 ⁇ L of the sorbents Protein A, zirconia, Heparin, MEP, GREEN 5, and 150 ⁇ L of the sorbents Blue Trisacryl and phenylpropylamine cellulose, were packed into
- 002.1413891.1 the individual elements of a WIZARD mini-column.
- the sorbents were equilibrated with 200 ⁇ L per well of the binding buffer (PBS (16v)/l M Tris-HCl (pH8, 9v)/H 2 O (75v)).
- a sample volume of 100 ⁇ L (five-fold dilution) of a solution of biomolecular components was passed through the column.
- the column elements were isolated and the sorbed materials were eluted.
- the eluates were analyzed by mass spectrometry and the results were compared to the same mass spectrographic analysis of a sample derived using a single column.
- the method of the invention provided almost two-fold more peaks (89% more) than the prior art method.
- the present invention also provides apparatuses and kits for fractionating complex mixtures of biomolecular components in accordance with the description provided above.
- the present invention provides an apparatus for prefractionating a complex mixture of biomolecular components.
- the apparatus includes a plurality of sorbents described above having different adsorption specificities for different biomolecular components.
- the sorbents are coupled serially and in fluidic communication such that introduction and passage of the mixture in a buffered solution as described above is effective to remove at least a portion of the components from the complex mixture.
- Various embodiments of these elements can be provided as described above.
- the sorbents can be arranged to provide a progression of specificities for a type of biomolecular component. Such a progression can be linear.
- the sorbents can also be provided as a substantially contiguous component-sequestering body.
- the sorbents can be arranged in a columnar assemblage or in an array of columns, such as provided by a series of 96-well plates.
- the sorbents are chosen for the apparatus to include: (a) a high specificity sorbent, (b) a moderate specificity sorbent material, and (c) a low specificity sorbent material.
- the invention provides a kit comprising a plurality of sorbents characterized by different adsorption specificities for different biomolecular component types and a compatible buffer.
- the combination is chosen such that when the materials are coupled in a series arrangement, introduction and serial passage of a buffered solution including (i) said complex mixture and (ii) said buffer through said series arrangement of materials is effective to capture substantially all of said plurality of biomolecular components from said complex mixture.
- the sorbents are chosen for the apparatus to
- D(P 1413R91 1 include: (a) a high specificity sorbent, (b) a moderately specific sorbent material, and (c) a low specificity sorbent material.
- the vacuum unit came from Whatman (Clifton, NJ, USA).
- the MICROMIX mixer was from DPC (Los Angeles, CA, USA).
- the MINIPULS III peristaltic pump was from Gilson (Middleton, WI, USA).
- Q-HYPERD F ® PROTEIN A CERAMIC HYPERD ® , BLUE TRIS ACRYL ® , HEPARIN HYPERD ® , MEP-HYPERCEL ® , immobilized Green 5 on cellulose, zirconia and phenylpropylamine cellulose sorbents were purchased from commercial sources (Ciphergen/BioSepra, 48 Avenue des Genottes, Cergy St. Christophe, France).
- SILENT SCREEN LOPRODYNE filter plates were purchased from NUNC (Rochester, NY, USA). WIZARD mini-columns were purchased from Promega (Madison, WI, USA). Sinapinic acid (SPA) was purchased from Ciphergen Bioinstruments (Fremont, CA, USA). One molar Tris-HCl pH 8 stock buffer was purchased from Invitrogen (Carlsbad, CA, USA). Human serum was purchased from Intergen (Norcross, GA, USA). Bovine insulin, PBS buffer, Trifluoro-acetic acid (TFA), isopropanol (IPA) 3 acetonitrile (ACN), ammonia 29% (NH 4 OH) solution were purchased from Sigma-Ultra. Urea, CHAPS, Trisma base, octyl-glucopyranoside (OGP), HEPES, sodium acetate, and sodium citrate were purchased from Sigma-Aldrich (St. Louis, MO, USA).
- a sample of denatured human serum was prepared by combining 2 ml of human serum with 2.5 ml of a 9 M urea-2% CHAPS solution over a period of about one hour at room temperature. The solution was aliquoted and frozen. Then 0.4 ml this denatured serum
- 002.1413891.1 was added of 36 ⁇ l of a IM Tris-HCl pH 9 stock buffer, 100 ⁇ l of the 9 M urea-2% CHAPS solution, and 364 ⁇ l of DI water to achieve a total 20% dilution of the human serum.
- a sample pool of the solutions having a volume of 30 ⁇ l was half-diluted in a binding (0.5M NaCl in 0.1M sodium phosphate pH 7 (IMAC30), 0.1M Sodium acetate pH 4 (CMlO), 5OmM Tris-HCl pH 9 (QlO), and 0.1% TFA, 10% acetonitrile (H50))corresponding to the ProteinChip array that was used (IMAC30, CMlO, QlO or H50 arrays). After 30 min. incubation at RT, the array was washed twice with 150 ⁇ L of the binding buffer and extensively washed with deionized (DI) water.
- DI deionized
- Example 1 Multiple Chemistry Fractionation of Human Serum on a 96-Well Filter Plate
- Each filter-plate was dedicated to only one sorbent chemistry and filled with 75 ⁇ L of the same sorbent per well, except for Blue-Trisacryl and phenylpropylamine cellulose where 150 ⁇ l of each were used per well.
- Each sorbent was equilibrated by adding 200 ⁇ L per well of the binding buffer (PBS (16v)/l M Tris-HCl (pH8, 9v)/H 2 O (75v)), with 5 min. soaking followed by vacuum removal of the buffer. The equilibration procedure was repeated
- plate 2 was transferred to plate 3 (Blue Trisacryl) as described above, and the supernatant of plate 1 was transferred to plate 2. Then plate 1 received a second aliquot (160 ⁇ L) of the binding buffer for a second wash. The three plates 1-3 were incubated on the mixer for 20 min. The same procedure was continued where the supernatants from any
- a sample volume of 100 ⁇ L of denatured human serum (bovine insulin-spiked or straight) diluted five-fold in 40 mM Tris-HCl pH 9 buffer (See described protocol in Section 4.2.5.1) was added to the sorbent incubated for 45 min. on the mixer (intensity setting 7). The sorbent supernatant was then filtered-off directly to a clean 96-well plate to give the flow- through fractions. Then, 100 ⁇ L of a 50 mM Tris-HCl pH 9/0.1%OGP buffer was added to the beads and the combination was incubated for 10 min. on the mixer (intensity setting 7).
- step-elutions by pH decrease were started by the addition of 100 ⁇ L of a 50 mM HEPES pH 7/0.1%OGP buffer to the beads with incubation for 10 min on the mixer (intensity setting 7). After vacuum-transfer of the HEPES supernatant in another clean 96- well plate, the same step was repeated; and the two HEPES eluents were pooled together to
- the Multiple chemistry fractionation method of the invention allows almost the doubling the number of unique peaks (clustered 4-arrays) as well as the total number of peaks (sum of 4-arrays) when compared to the standard fractionation on Q-HYPERD (See Table 5 and Figure 3).
- Each disposable WIZARD column was filled with 125 ⁇ L of one of the seven different sorbents as follows: Protein A (1 unit), Blue Trisacryl (3 units), Heparin (1 unit), MEP (1 unit), Green 5 (1 unit), and phenylpropylamine (2 units).
- the stack of 10 units was equilibrated with 3 ml of binding buffer (PBS (16v)/l M Tris-HCl pH8 (9v)/H 2 O (75v)) at a
- FIG. 4 illustrates the benefit of the method of the invention.
- a sample spiked with insulin was detected on a specific sorbent chemistry (MEP-HYPERCEL, column A).
- MEP-HYPERCEL specific sorbent chemistry
- Figure 5 shows the direct benefit on sensitivity provided by the method of invention.
- the ability of the method of the invention to capture insulin on a specific sorbent chemistry provides detection at concentrations as low as 1 fMol/ ⁇ L in human serum (column A).
- Q-HyperD single-chemistry fractionation methods
- a 2-log reduction in sensitivity was observed (100 fMol/ ⁇ L, column B).
- hydrophobic sorbents are able to form hydrophobic association with proteins in physiological conditions of ionic strength and pH as a result of their unique chemical structure (see international patent application No. PCT/US2005/001304, which is hereby incorporated by reference). This property is very useful for this example since the buffer used for protein interaction is the same for all selected sorbents and do not comprise lyotropic agents as is generally the case for hydrophobic chromatography.
- Figures 6 and 7 demonstrate that each sorbent captures different protein. Most of proteins of different category were sequentially captured by C2 and C4 sorbents. The C8 column adsorbed unique species previously uncaptured by the prior sorbents.
- Cl has a narrow specificity for hydrophobic associations and, therefore, interacts with the most hydrophobic species.
- the most hydrophobic sectional column (C6) has a large specificity for hydrophobic associations and, therefore, is expected to adsorb all proteins that escaped capture by previous columns, including those proteins with a weak property to form hydrophobic associations.
- the series of HIC sorbents are evaluated in separate experiments using two different buffers. In one instance, the same conditions described in the previous example are used, and in a second a physiological buffer containing 2M urea is used. The latter buffer is used to slightly reduce the hydrophobic interaction of proteins for the sorbents.
- Figure 8 shows that proteins adsorbed in the presence of urea 2 M and eluted from different sectional columns possess different electrophoresis mobilities and masses.
- Figure 9 provides SELDI MS analysis of protein
- Figure 10 provides SELDI MS analysis of protein fractions eluted from Cl, C2, C3, C4, C6 and FT (flowthrough), using a CMlO ProteinChip Array using a physiological buffer containing 2M urea.
- the present invention provides methods, apparatus, and kits for fractionating or prefractionating complex mixtures of biomolecular components.
- the methods, apparatus, and kits provided by the present invention provide means for detecting biomolecular components with greater sensitivity and ease that heretofore possible, thus providing better research and diagnostic tools among many other applications.
- other examples of the many of the materials described herein can be used as described herein without departing from the spirit of scope of the invention.
- any material effective as a sorbent for biomolecular components or any method of detecting and identifying such component can be used as described herein.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05761271A EP1781778A4 (en) | 2004-06-16 | 2005-06-16 | Multichemistry fractionation |
JP2007516785A JP2008503725A (en) | 2004-06-16 | 2005-06-16 | Multi-chemistry fractionation |
CA002583081A CA2583081A1 (en) | 2004-06-16 | 2005-06-16 | Multichemistry fractionation |
US10/558,649 US20070142629A1 (en) | 2004-06-16 | 2005-06-16 | Multichemistry fractionation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58062704P | 2004-06-16 | 2004-06-16 | |
US60/580,627 | 2004-06-16 | ||
US59131904P | 2004-07-27 | 2004-07-27 | |
US60/591,319 | 2004-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006007429A1 true WO2006007429A1 (en) | 2006-01-19 |
Family
ID=35784201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/021489 WO2006007429A1 (en) | 2004-06-16 | 2005-06-16 | Multichemistry fractionation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070142629A1 (en) |
EP (1) | EP1781778A4 (en) |
JP (1) | JP2008503725A (en) |
CA (1) | CA2583081A1 (en) |
WO (1) | WO2006007429A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8742331B2 (en) | 2008-02-15 | 2014-06-03 | Sigma-Aldrich, Co. | Imidazolium-based liquid salts and methods of use thereof |
US8980643B2 (en) | 2008-02-15 | 2015-03-17 | Sigma-Aldrich Co., Llc | Dicationic liquid salts and methods of use thereof |
CN104981476A (en) * | 2012-12-05 | 2015-10-14 | 德国杰特贝林生物制品有限公司 | A method Of Purifying Therapeutic Proteins |
US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
US10274466B2 (en) | 2013-07-12 | 2019-04-30 | Genentech, Inc. | Elucidation of ion exchange chromatography input optimization |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009132330A2 (en) * | 2008-04-25 | 2009-10-29 | Biotrove, Inc. | Separation cartridges and methods for fabrication and use thereof |
JP2013522592A (en) * | 2010-03-10 | 2013-06-13 | パーフィニティ バイオサイエンシズ インコーポレイテッド | Method for recognition and quantification of multiple analytes in a single analysis |
US8455202B2 (en) | 2010-03-10 | 2013-06-04 | Perfinity Biosciences, Inc. | Affinity selector based recognition and quantification system and method for multiple analytes in a single analysis |
US20170370813A1 (en) * | 2015-01-09 | 2017-12-28 | Children's Medical Center Corporation | Methods of membrane-based proteomic sample preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378816A (en) * | 1992-12-16 | 1995-01-03 | Berlex Laboratories, Inc. | Methods for high purity chromatographic separation of proteins having EGF-like binding domains |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE458818B (en) * | 1987-11-27 | 1989-05-16 | Svenska Mejeriernas Riksforeni | PROCEDURE FOR EXTRACTION OF PURE FRACTIONS OF LACTOPEROXIDAS AND LACTOFERRIN FROM MILK SERUM |
US5057437A (en) * | 1988-07-27 | 1991-10-15 | Bio-Rad Laboratories, Inc. | Method for broad spectrum drug detection |
US5290685A (en) * | 1990-02-22 | 1994-03-01 | Meiji Milk Products Company Limited | Method for separation and concentration of phosphopeptides |
DK165090D0 (en) * | 1990-07-09 | 1990-07-09 | Kem En Tec As | CONLOMERATED PARTICLES |
US6096870A (en) * | 1994-01-05 | 2000-08-01 | Sepragen Corporation | Sequential separation of whey |
JPH07267990A (en) * | 1994-03-29 | 1995-10-17 | Cosmo Sogo Kenkyusho:Kk | Method for separating and purifying gamma-seminoprotein |
JP3745805B2 (en) * | 1995-10-24 | 2006-02-15 | 日本ケミカルリサーチ株式会社 | Purification method of thrombomodulin |
JP3113907B2 (en) * | 1997-09-19 | 2000-12-04 | 国立公衆衛生院長 | Multistage solid phase for concentrating components in water and method for concentrating components in water using the same |
US20030091976A1 (en) * | 2001-11-14 | 2003-05-15 | Ciphergen Biosystems, Inc. | Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry |
US7670833B2 (en) * | 2002-08-08 | 2010-03-02 | Biochain Institute, Inc. | High throughput analysis for molecular fractions |
-
2005
- 2005-06-16 US US10/558,649 patent/US20070142629A1/en not_active Abandoned
- 2005-06-16 JP JP2007516785A patent/JP2008503725A/en active Pending
- 2005-06-16 WO PCT/US2005/021489 patent/WO2006007429A1/en active Application Filing
- 2005-06-16 CA CA002583081A patent/CA2583081A1/en not_active Abandoned
- 2005-06-16 EP EP05761271A patent/EP1781778A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378816A (en) * | 1992-12-16 | 1995-01-03 | Berlex Laboratories, Inc. | Methods for high purity chromatographic separation of proteins having EGF-like binding domains |
Non-Patent Citations (2)
Title |
---|
See also references of EP1781778A4 * |
TANDON N ET AL: "Isolation and characterization of platelet glycoprotein IV(CD36).", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 264, no. 13, May 1989 (1989-05-01), pages 7570 - 7575, XP002993906 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8742331B2 (en) | 2008-02-15 | 2014-06-03 | Sigma-Aldrich, Co. | Imidazolium-based liquid salts and methods of use thereof |
US8980643B2 (en) | 2008-02-15 | 2015-03-17 | Sigma-Aldrich Co., Llc | Dicationic liquid salts and methods of use thereof |
CN104981476A (en) * | 2012-12-05 | 2015-10-14 | 德国杰特贝林生物制品有限公司 | A method Of Purifying Therapeutic Proteins |
EP2928905A4 (en) * | 2012-12-05 | 2016-06-08 | Csl Behring Gmbh | A method of purifying therapeutic proteins |
CN104981476B (en) * | 2012-12-05 | 2018-10-09 | 德国杰特贝林生物制品有限公司 | A kind of method of purification therapy protein |
US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
EP3483173A1 (en) * | 2012-12-05 | 2019-05-15 | CSL Behring GmbH | Separation of fibrinogen, fviii and/or vwf from plasma proteases by hcic |
US11426680B2 (en) | 2012-12-05 | 2022-08-30 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic protein depleted solution |
US9598461B2 (en) | 2013-02-04 | 2017-03-21 | Csl Behring Gmbh | Method of purifying therapeutic proteins |
US10274466B2 (en) | 2013-07-12 | 2019-04-30 | Genentech, Inc. | Elucidation of ion exchange chromatography input optimization |
US10921297B2 (en) | 2013-07-12 | 2021-02-16 | Genentech, Inc. | Elucidation of ion exchange chromatography input optimization |
Also Published As
Publication number | Publication date |
---|---|
EP1781778A4 (en) | 2007-09-12 |
EP1781778A1 (en) | 2007-05-09 |
US20070142629A1 (en) | 2007-06-21 |
JP2008503725A (en) | 2008-02-07 |
CA2583081A1 (en) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5123847B2 (en) | Fluid engineering equipment | |
WO2006007429A1 (en) | Multichemistry fractionation | |
Gilar et al. | Advances in sample preparation in electromigration, chromatographic and mass spectrometric separation methods | |
Slentz et al. | Protein proteolysis and the multi-dimensional electrochromatographic separation of histidine-containing peptide fragments on a chip | |
US7482169B2 (en) | Low dead volume extraction column device | |
US6358692B1 (en) | High speed, automated, continuous flow, multi-dimensional molecular selection and analysis | |
US7790475B2 (en) | Apparatuses and methods for reducing albumin in samples | |
KR20070001927A (en) | Fractionator and method of fractionation | |
Gajdosik et al. | Sample displacement chromatography as a method for purification of proteins and peptides from complex mixtures | |
JPH06510600A (en) | Method and device for detecting trace contaminants | |
US8501116B2 (en) | Low dead volume extraction column device | |
Hedhammar et al. | Chromatographic methods for protein purification | |
Liu et al. | Quantitative comparisons of large numbers of human plasma samples using TMT10plex labeling | |
Ribeiro et al. | Recent stationary phase‐based fractionation strategies in proteomic analysis | |
Majors et al. | Micropipette Tip–Based Sample Preparation for Bioanalysis | |
Guerrier et al. | Solid-phase fractionation strategies applied to proteomics investigations | |
Guerrier et al. | Protocol for the purification of proteins from biological extracts for identification by mass spectrometry | |
Millea et al. | Subproteomics in analytical chemistry: Chromatographic fractionation techniques in the characterization of proteins and peptides | |
EP1300679A2 (en) | Molecular selection and analysis | |
JP2005232156A (en) | Solution of purified component of living body,method for separating the component of the living body and apparatus for separating the component of the living body | |
US20080160629A1 (en) | Methods and systems for off-line multidimensional concentration and separation of biomolecules | |
Tuzimski et al. | Use of a database of plots of pesticide retention (RF) against mobile-phase composition. Part II. TLC as a pilot technique for transferring retention data to HPLC, and use of the data for preliminary fractionation of a mixture of pesticides by micropreparative column chromatography | |
Boschetti et al. | Mixed-Bed Affinity Chromatography: Principles and Methods | |
Zolotarjova et al. | methods for proteomic analysis | |
Wehr | Sample preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2007142629 Country of ref document: US Ref document number: 10558649 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007516785 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2583081 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005761271 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005761271 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10558649 Country of ref document: US |